HPCM
ANIX icon

Hunter Perkins Capital Management’s Anixa Biosciences ANIX Stock Holding History

Hunter Perkins Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,653
Closed -$54K – 89
2020
Q4 		$54K Buy
+17,653
New +$44.4K 0.01% 173

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Hunter Perkins Capital Management's ANIX Position: Q1 2021 in Review

Hunter Perkins Capital Management sold out of Anixa Biosciences (ANIX) in Q1 2021, closing a stake of 17,653 shares — an estimated $54K sold.

Hunter Perkins Capital Management first reported a position in ANIX in Q4 2020 and held it in 1 quarter. The position peaked at $54K in Q4 2020. 29 funds tracked by Wall St. Rank hold ANIX as of Q1 2021.

  • Hunter Perkins Capital Management reported no remaining Anixa Biosciences position as of Q1 2021 after selling out during the quarter.
  • Hunter Perkins Capital Management sold 17,653 Anixa Biosciences shares in Q1 2021, an estimated $54K.
  • Hunter Perkins Capital Management first reported a position in Anixa Biosciences in Q4 2020 and held it in 1 quarter.
  • Hunter Perkins Capital Management's Anixa Biosciences position peaked at $54K in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2021.

Based on Hunter Perkins Capital Management's 13F filing for Q1 2021, filed 28 Apr 2021.